Lucy Crossley

Mrs. Lucy Crossley

UK Health Security Agency, London, City of London, UK
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
SFSTEPHEN FINDLAY-WILSON
STEPHEN FINDLAY-WILSON
LCLucy Crossley
Lucy Crossley
FSF. Javier Salguero
F. Javier Salguero
ITInes Ruedas Torres
Ines Ruedas Torres
SFSusan Fotheringham
Susan Fotheringham
SDStuart Dowall
Stuart Dowall
Nipah virus (NiV) is an emerging pathogen that can cause severe respiratory illness and encephalitis in humans. The main reservoir is fruit bats, distributed across a large geographical area that includes Australia, Southeast Asia, and Africa. Incursion into humans is widely reported through exposure of infected pigs, ingestion of contaminated food, or through contact with an infected person. With no approved treatments or vaccines, NiV poses a threat to human public health and has epidemic potential. To aid with the assessment of emerging interventions being developed, an expansion of preclinical testing capability is required. Given variations in the model parameters observed in different sites during establishment, optimisation of challenge routes and doses is required. Upon evaluating the hamster model, an intranasal route of challenge was compared with intraperitoneal delivery, demonstrating a more rapid dissemination to wider tissues in the latter. A dose effect was observed between those causing respiratory illness and those resulting in neurological disease. The data demonstrate the successful establishment of the hamster model of NiV disease for subsequent use in the evaluation of vaccines and antivirals.

30 November 2023 in Viruses
Verified
Journal Article
Open access
PDF file
VGVictoria A. Graham
Victoria A. Graham
LELinda Easterbrook
Linda Easterbrook
EKEmma Kennedy
Emma Kennedy
EREmma Rayner
Emma Rayner
SFSTEPHEN FINDLAY-WILSON
STEPHEN FINDLAY-WILSON
SDStuart Dowall
Stuart Dowall
Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic pathogen causing disease in livestock and humans. Whilst initially restricted to the African continent, recent spread to the Arabian Peninsula has highlighted the likelihood of entry into new regions. Due to the absence of a regulatory-approved human vaccine, work is ongoing to develop and assess countermeasures. As such, small animal models play a pivotal role in providing information on disease pathogenesis and elucidating which intervention strategies confer protection. To develop and establish the BALB/c mouse model, we challenged mice with RVFV grown from two separate cell lines: one derived from mosquitoes (C6/36) and the other mammalian derived (Vero E6). Following infection, we assessed the clinical course of disease progression at days 1 and 3 post-challenge and evaluated viral tropism and immune analytes. The results demonstrated that RVFV infection was affected by the cell line used to propagate the challenge virus, with those grown in insect cells resulting in a more rapid disease progression. The lowest dose that caused uniform severe disease remained the same across both virus preparations. In addition, to demonstrate reproducibility, the lowest dose was used for a subsequent infection study using male and female animals. The results further demonstrated that male mice succumbed to infection more rapidly than their female counterparts. Our results establish an RVFV mouse model and key parameters that affect the course of disease progression in BALB/c mice.

27 September 2024 in Viruses
Verified
Journal Article
Open access
PDF file
VGVictoria A. Graham
Victoria A. Graham
LELinda Easterbrook
Linda Easterbrook
EREmma Rayner
Emma Rayner
SFSTEPHEN FINDLAY-WILSON
STEPHEN FINDLAY-WILSON
LCLucy Crossley
Lucy Crossley
SDStuart Dowall
Stuart Dowall
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus causing a debilitating febrile illness with rheumatic disease symptoms of arthralgia and arthritis. Since its spread outside of Africa in 2005, it continues to cause outbreaks and disseminates into new territories. Intervention strategies are urgently required, including vaccination and antiviral approaches. To test efficacy, the use of small animal models is required. Two mouse strains, A129, with a deficiency in their type-I interferon (IFN) receptor, and C57BL/6 are widely used. A direct comparison of these strains alongside the wild-type parental strain of the A129 mice, 129Sv/Ev, was undertaken to assess clinical disease progression, viral loads in key tissues, histological changes and levels of sera biomarkers. Our results confirm the severe disease course in A129 mice which was not observed in the parental 129Sv/Ev strain. Of the two wild-type strains, viral loads were higher in 129Sv/Ev mice compared to C57BL/6 counterparts. Our results have established these models and parameters for the future testing of vaccines and antiviral approaches.

26 February 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SFStephen Findlay-Wilson
Stephen Findlay-Wilson
NTNazia Thakur
Nazia Thakur
LCLucy Crossley
Lucy Crossley
LELinda Easterbrook
Linda Easterbrook
FSFrancisco J. Salguero
Francisco J. Salguero
SDStuart Dowall
Stuart Dowall
Introduction: Nipah virus (NiV) is one of a group of highly pathogenic viruses classified within the Henipavirus genus. Since 2012 at least 11 new henipa-like viruses have been identified, including from new locations and reservoir hosts; the pathogenicity of these new viruses has yet to be determined, but two of them have been associated with morbidity, including fatalities.Methods: The efficacy and cross-reactivity of two vaccine candidates derived from the soluble glycoproteins of both NiV and Hendra virus (HeV) was evaluated in our recently established hamster model.Results: Both vaccine preparations resulted in strong humoral responses against NiV antigenic targets, demonstrating cross-reactive immunity. Efficacy was determined through challenge of hamsters with NiV Malaysian (NiV-M) strain. 100% of the hamsters survived a lethal challenge dose after prime/boost immunisation with glycoproteins derived from both NiV and HeV in the presence of adjuvant, with clinical signs and pathology being significantly reduced in immunised animals.Discussion: This is first time the NiV and HeV soluble glycoproteins have been compared in the NiV-M hamster challenge model in the presence of Alhydrogel and AddaVax, providing evidence that glycoproteins from closely related henipavirus species can provide cross-protectivity against infection from alternate henipaviruses, supporting the potential of an effective pan-henipavirus vaccine for use in a frontline outbreak response.

6 February 2026 in Medical and Veterinary Entomology
Verified
Journal Article
Open access
AVAlexander Vaux
Alexander Vaux
HHHarrison Hardy
Harrison Hardy
LCLucy Crossley
Lucy Crossley
CJColin Johnston
Colin Johnston
AAAnthony J. Abbott
Anthony J. Abbott
JMJolyon Medlock
Jolyon Medlock
Effective surveillance of mosquito populations is critical to monitoring and mitigating the spread of mosquito‐borne diseases (MBDs). This study evaluated the relative trapping efficiency of two widely used adult mosquito traps—the Biogents BG‐Sentinel (BGS) and the Mosquito Magnet® Executive (MM)—on British mosquitoes across four wetlands in south‐east England over a 12‐week period. A third trap, a Box‐Gravid trap fitted with an FTA™ card, was deployed to detect arboviruses such as West Nile virus (WNV) via saliva collection. A total of 11,584 adult female mosquitoes representing 15 species were collected. The MM trap captured a significantly higher total number of mosquitoes, while the BGS trap demonstrated greater species evenness and was significantly more effective at catching Culex ( Culex ) pipiens L., 1758. Spatial variation strongly influenced catch rates, with significant differences between wetlands. No evidence of WNV was detected in any mosquito pools or FTA™ cards. While both trap types yielded similar species richness, the MM trap may be optimal for collecting large sample sizes of mammalophagic species, whereas the BGS is better suited for capturing enzootic vectors such as Culex pipiens s.l. , and a broader spectrum of species. These findings provide evidence‐based recommendations for future UK wetland surveillance and enhance preparedness for emerging vector‐borne disease risks.

1 July 2025 in Journal of General Virology
Verified
Journal Article
Open access
LCLucy Crossley
Lucy Crossley
SFSTEPHEN FINDLAY-WILSON
STEPHEN FINDLAY-WILSON
LELinda Easterbrook
Linda Easterbrook
EKEmma Kennedy
Emma Kennedy
FSF. Javier Salguero
F. Javier Salguero
SDStuart Dowall
Stuart Dowall
A corrigendum of this article has been published full details can be found at https://doi.org/10.1099/jgv.0.002162 . Mpox (formerly known as monkeypox) virus (MPXV) is the zoonotic pathogen of mpox disease in humans. Its increasing emergence outside of its endemic area has heightened the importance of investigating the virus’ prevalence and maintenance in sylvatic reservoirs. The common brown rat (Rattus norvegicus) can inhabit almost anywhere in the UK, posing a threat to zoonotic transmission to humans. Two independent studies were carried out; the first investigated the susceptibility of brown rats to MPXV infection with a clade IIb mpox strain via two challenge routes: intranasal and intradermal. The second study considered the transmission of MPXV between challenged and naïve brown rats. All animals were asymptomatic to mpox disease, although enzyme-linked immunosorbent assay (ELISA) confirmed subclinical infection in challenge groups. In the susceptibility study, reverse transcription PCR (RT-PCR) detected mpox DNA in the lung tissue and throat swabs within the intranasally inoculated group, in addition to viable virus observed from the intranasal throat swabs. In contrast, no virus was detected in either tissues or swabs in the intradermally inoculated group or control group. RT-PCR results from the transmission study detected mpox DNA in tissues and throat swabs taken from challenged animals. Viable virus was observed from tissues and swabs of intranasally challenged animals with infectious titres of ~102–104 TCID50 per millilitre. ELISA assays in the transmission study showed replicable results compared to the first susceptibility study in directly challenged animals alongside evidence of seroconversion in co-housed naïve animals. In conclusion, brown rats are susceptible to MPXV infection, as they have been demonstrated to maintain viable virus in the absence of clinical signs. Viral transmission of MPXV from infected rats to naïve rats was not observed by RT-PCR, although naïve rats did show antibody responses when exposed to infected rats indicating exposure to virus.